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Abstract
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 
recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes 
trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 
(GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events 
(MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be 
considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered 
in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of 
high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with 
heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with 
CKD (eGFR 30 to ≤60 ml min−1 [1.73 m]−2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent 
the progression of CKD, hHF, MACE and cardiovascular death.
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CVOT Cardiovascular outcomes trial
DAPA-HF Dapagliflozin and Prevention of
Adverse Outcomes in Heart Failure
DPP-4 Dipeptidyl peptidase-4
DECLARE–TIMI 58 Dapagliflozin Effect on
Cardiovascular Events–Thrombolysis
in Myocardial Infarction 58
EF Ejection fraction
GLP-1 Glucagon-like peptide 1
GLP-1 RA GLP-1 receptor agonist
HF Heart failure
HFrEF Heart failure with reduced ejection
fraction
hHF Hospitalisation for heart failure
MACE Major adverse cardiovascular event
REWIND Researching Cardiovascular Events
with a Weekly Incretin in Diabetes
SGLT2 Sodium–glucose cotransporter 2
SGLT2i SGLT2 inhibitor
UACR Urinary albumin-to-creatinine ratio
The American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD) requested a
brief update of the 2018 recommendations on management
of hyperglycaemia [1, 2], based on the important research
findings published in 2019, with a particular focus on new
data from large cardiovascular outcomes trials (CVOTs).
The authors began work on the brief update in July 2019
and submitted it for publication in Diabetes Care and
Diabetologia in October 2019. Work was conducted over a
series of phone calls and by electronic interactions. This brief
update provides a summary of the implications of this new
evidence on recommendations for the management of
hyperglycaemia in type 2 diabetes (see text box), which will
be addressed more fully in the ADA Standards of Medical
Care in Diabetes – 2020 (https://professional.diabetes.org/
SOC). It should be considered in conjunction with the 2018
consensus report [1, 2].
The Researching Cardiovascular Events with a Weekly
Incretin in Diabetes (REWIND) trial of the glucagon-like
peptide 1 (GLP-1) receptor agonist dulaglutide included a
greater proportion of individuals with type 2 diabetes with
high cardiovascular risk but without prior established
cardiovascular disease (CVD) (68.5%) and with longer
follow-up (median 5.4 years) than prior CVOTs [3]. The
primary major adverse cardiovascular event (MACE)
outcome occurred in 2.7 per 100 patient-years with an HR
of 0.88 (95% CI 0.79, 0.99) in favour of dulaglutide. There
was no difference in the MACE effect in the subpopulations
with and without a history of CVD, although the treatment
effect of dulaglutide did not reach statistical significance when
the groups were considered separately. Most other CVOTs
with GLP-1 receptor agonists have included a minority of
patients with risk factors only but without evidence of benefit
onMACE outcomes in the lower-risk subgroups.Whether the
differences in outcomes in trial subgroups without established
CVD are related to study details or to the assigned therapy is
uncertain. In REWIND, prior CVDwas defined as a history of
myocardial infarction, ischaemic stroke, unstable angina with
ECG changes, myocardial ischaemia on imaging or stress test,
or coronary, carotid or peripheral revascularisation. We previ-
ously recommended that established CVD was a compelling
indication for treatment with a GLP-1 receptor agonist or
sodium–glucose cotransporter 2 (SGLT2) inhibitor. We now
also suggest that to reduce risk of MACE, GLP-1 receptor
agonists can also be considered in patients with type 2
diabetes without established CVD with indicators of high
risk, specifically, patients aged 55 years or older with coro-
nary, carotid or lower extremity artery stenosis >50%, left
ventricular hypertrophy, an eGFR <60 ml min−1
[1.73 m]−2 or albuminuria. To date, the level of evidence
to support the use of GLP-1 receptor agonists for primary
prevention is strongest for dulaglutide but lacking for other
GLP-1 receptor agonists.
The Dapagliflozin Effect on Cardiovascular Events–
Thrombolysis in Myocardial Infarction 58 (DECLARE–
TIMI 58) trial compared the SGLT2 inhibitor dapagliflozin
with placebo and also enrolled a greater proportion of partic-
ipants with type 2 diabetes without prior established CVD but
with multiple risk factors (59.4%) and with longer follow-up
(median 4.2 years) than other SGLT2 inhibitor trials [4].
Dapagliflozin demonstrated cardiovascular (CV) safety but
not a benefit for the MACE endpoint (HR 0.93, 95% CI
0.84, 1.03). Dapagliflozin was associated with benefit for the
co-primary efficacy endpoint of cardiovascular death or
hospitalisation for heart failure (hHF) with HR 0.83 (95% CI
0.73, 0.95) as well as renal endpoints. For MACE, the HR in
the multiple risk factor group without established atheroscle-
rotic vascular disease was 1.01, but this group had strong
evidence for benefit for the composite of cardiovascular death
or hHF. Meta-analysis of the SGLT2 inhibitor CVOTs suggest
a class effect to reduce hHF and chronic kidney disease
(CKD) progression across high and lower CVD risk
subgroups with no effect on MACE in the absence of
established atherosclerotic vascular disease [5].
Analysis of two SGLT2 inhibitor CVOTs, DECLARE–
TIMI 58 [6] and the Canagliflozin Cardiovascular
Assessment Study (CANVAS) Program [7], suggests that
the benefits of SGLT2 inhibitors for hHF, MACE and cardio-
vascular death are greatest for those individuals with pre-
existing heart failure with reduced ejection fraction (HFrEF)
compared with those without HFrEF. It is important to note
that hHF was a secondary outcome, relatively low numbers of
patients had HF at baseline, and data on ejection fraction (EF)
were only available for a proportion of patients. In
DECLARE–TIMI 58, individuals with HF but no reduction
of EF as well as those without HF did not seem to benefit from
dapagliflozin treatment to lower MACE and cardiovascular
death outcomes. The benefit for hHF was strongest for those
who at baseline had an EF <30%, strong for those with an EF
<45%, and marginal for those with an EF ≥45% or those
without HF. The Dapagliflozin and Prevention of Adverse
Outcomes in Heart Failure (DAPA-HF) trial of dapagliflozin
was the first heart failure outcome trial of a diabetes
medication [8]. Recruitment included patients with and with-
out type 2 diabetes with heart failure and an EF ≤40% and
demonstrated benefits for reduction of the primary composite
endpoint of CV death, hHF and urgent HF visits, as well as for
HF events and mortality (CVand total) considered separately.
We now suggest that SGLT2 inhibitors are recommended
in patients with type 2 diabetes and HF, particularly those
with HFrEF, to reduce hHF, MACE and CV death.
The REWIND trial of the GLP-1 receptor agonist
dulaglutide had no lower limit to HbA1c for eligibility and
demonstrated equivalent efficacy for reduction of MACE
above and below the median HbA1c of 55 mmol/mol (7.2%)
[3]. None of the CVOTs of SGLT2 inhibitors with primary
MACE endpoints have recruited patients with an HbA1c
<48 mmol/mol (<6.5%), and there is little data to inform clin-
ical decision making for patients with an HbA1c <53 mmol/
mol (<7%) [9]. However, the outcome benefits observed in the
CVOTs do not appear restricted to patients with an elevated
HbA1c. That said, the DAPA-HF trial recruited patients with
Changes to consensus recommendations
We previously recommended that, in the setting of type 2 diabetes, established CVD was a compelling indi-
cation for treatment with a GLP-1 receptor agonist or SGLT2 inhibitor. We now further suggest the following:
General consideration
In appropriate high-risk individuals with established type 2 diabetes, the decision to treat with a GLP-1 
receptor agonist or SGLT2 inhibitor to reduce MACE, hHF, CV death or CKD progression should be 
considered independently of baseline HbA1c or individualised HbA1c target.  
Providers should engage in shared decision making around initial combination therapy in new-onset 
cases of type 2 diabetes.
GLP-1 receptor agonist recommendations
For patients with type 2 diabetes and established atherosclerotic CV disease (such as those with prior 
myocardial infarction, ischaemic stroke, unstable angina with ECG changes, myocardial ischaemia on 
imaging or stress test, or revascularisation of coronary, carotid or peripheral arteries) where MACE is the 
gravest threat, the level of evidence for MACE benefit is greatest for GLP-1 receptor agonists. 
To reduce risk of MACE, GLP-1 receptor agonists can also be considered in patients with type 2 diabe-
tes without established CVD with indicators of high risk, specifically, patients aged 55 years or older with 







For patients with or without established atherosclerotic CVD, but with HFrEF (EF <45%) or CKD (eGFR 




² or UACR >30 mg/g, particularly UACR >300 mg/g), the level of evidence for
benefit is greatest for SGLT2 inhibitors. 
SGLT2 inhibitors are recommended in patients with type 2 diabetes and HF, particularly those with 
HFrEF, to reduce hHF, MACE and CV death. 
SGLT2 inhibitors are recommended to prevent the progression of CKD, hHF, MACE and CV death in 
patients with type 2 diabetes with CKD. 
Patients with foot ulcers or at high risk for amputation should only be treated with SGLT2 inhibitors after 
careful shared decision making around risks and benefits with comprehensive education on foot care and 
amputation prevention.
HFrEF with and without diabetes [8]. The benefit for reduc-
tion of mortality rate and HF events with dapagliflozin was
significant in both subgroups suggesting that the effects of
dapagliflozin on these endpoints is independent of HbA1c
[8].We now recommend that in appropriate high-risk indi-
viduals with established type 2 diabetes, the decision to
treat with a GLP-1 receptor agonist or SGLT2 inhibitor
to reduce MACE, hHF, cardiovascular death or CKD
progression should be considered independently of base-
line HbA1c or individualised HbA1c target. That said, there
are no specific analyses addressing HbA1c <48 mmol/mol
(<6.5%). We continue to recommend that substituting a drug
with known CVD, CKD and hHF benefit for one without
known benefit in high-risk patients is reasonable when
patients are at individualised glycaemic targets.
The Canagliflozin and Renal Events in Diabetes with
Established Nephropathy Clinical Evaluation (CREDENCE)
trial of the SGLT2 inhibitor canagliflozin was the first renal
outcome trial of a diabetes medication [10] with a primary
composite endpoint of end-stage kidney disease (dialysis,
transplantation or a sustained eGFR of <15 ml min−1
[1.73 m]−2), a doubling of the serum creatinine level or death
from renal or cardiovascular causes. The trial recruited
patients with type 2 diabetes and CKD on the maximally
tolerated dose of ACE inhibitors or angiotensin receptor
blockers (ARBs) with a urinary albumin-to-creatinine ratio
(UACR) of 300–5000 mg/g and an eGFR of 30 to
<90ml min−1 [1.73 m]−2. This trial demonstrated a clear bene-
fit of canagliflozin (100 mg) on multiple renal endpoints,
including progression to end-stage kidney disease, and on
cardiovascular mortality, MACE and hHF. Furthermore, the
CREDENCE results demonstrated that the benefits conferred
by canagliflozin in terms of reducing MACE, hHF, cardiovas-
cular mortality and renal endpoints were similar regardless of
baseline status for cardiovascular or CKD grade 2–3 [11]. We
now recommend that SGLT2 inhibitors should be used to
prevent hHF,MACE and CV death and the progression of
CKD in patients with type 2 diabetes with CKD. The bene-
fits are clear-cut for those with UACR >300 mg/g and eGFR
30–90 ml min−1 [1.73 m]−2 and less well established for lesser
grades of CKD based on secondary endpoint analyses of the
CVOT.
A concern in the CANVAS Program was the increased
risk of amputation with canagliflozin compared with placebo
[7]. In CREDENCE [10], although the risk of amputation
was higher overall than in other SGLT2 inhibitor trials, no
significant increase in risk was observed with canagliflozin
100 mg vs placebo (HR 1.11, 95% CI 0.79, 1.56). This may
be due to the risk mitigation strategies employed: exclusion
of patients with a history of a traumatic amputation within
12 months of screening, or an active foot ulcer, osteomyeli-
tis, gangrene or critical ischaemia of the lower extremity
within the 6 months of screening; and interruption of
therapy for emergence of any of the above with careful
consideration of the individual risks and benefits prior to
restarting canagliflozin after resolution of the event. We
now recommend that patients with foot ulcers or at high
risk for amputation should only be treated with SGLT2
inhibitors after careful shared decision making around
risks and benefits with comprehensive education on foot
care and amputation prevention.
Based on the studies published thus far, we believe that for
patients with type 2 diabetes and established atherosclerotic
CVD (such as those with prior myocardial infarction, isch-
aemic stroke, unstable angina with ECG changes, myocardi-
al ischaemia on imaging or stress test, or revascularisation of
coronary, carotid, or peripheral arteries) whereMACE is the
gravest threat, that the level of evidence forMACE benefit is
greatest for GLP-1 receptor agonists.
The Peptide Innovation for Early Diabetes Treatment 6
(PIONEER 6) cardiovascular safety trial of oral semaglutide,
a GLP-1 receptor agonist, involved 3183 patients with type 2
diabetes followed for only a median of 16 months, but provid-
ed adequate demonstration of cardiovascular safety (HR 0.79,
95% CI 0.57, 1.11) and a strong signal for reduction of CV
mortality rate (HR 0.49, 95% CI 0.27, 0.92) [12]. This formu-
lation of semaglutide has been approved for marketing in the
USA and a decision in the EU is expected soon.
For patients with or without established atherosclerotic
CVD, but with HFrEF or CKD (eGFR 30 to ≤60 ml min−1
[1.73 m]−2 or UACR >30 mg/g, particularly UACR
>300 mg/g), the level of evidence for benefit is greatest
for SGLT2 inhibitors. For patients with type 2 diabetes at
low cardiovascular risk and without CKD, there have been no
studies to examine the cardiovascular or renal benefit of GLP-
1 receptor agonists or SGLT2 inhibitors.
Some meta-analyses [5, 13, 14] suggest the presence of
heterogeneity in estimates for MACE and CV death with
GLP-1 receptor agonists, although this is mostly due to the
results of a single trial with lixisenatide. Likewise, there is
some heterogeneity in the estimate for CV death with
SGLT2 inhibitors. Whether differences in point estimates of
benefits and harms are the result of differences in the effects of
the medications, the design and conduct of the trials, or chance
effects is uncertain. Attention to patient-specific factors and
preferences, product labelling, meta-analyses, and the primary
research reports should drive individualised clinical decision
making with regards to prescribing particular medications
within a class. For many patients, treatment with a GLP-1
receptor agonist or SGLT2 inhibitor in some healthcare
settings involves considerable direct cost to them, and the
impact of this on their overall wellbeing needs to be factored
into decision making.
The Cardiovascular Outcome Study of Linagliptin vs
Glimepiride in Type 2 Diabetes (CAROLINA) trial







































































































Fig. 2 Glucose-lowering medication in type 2 diabetes: overall approach. Modified from [2] with permission from Springer. ©European Association for
the Study of Diabetes and American Diabetes Association 2018
dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin or to
receive the sulfonylurea glimepiride to evaluate a primary
MACE endpoint. No between-group difference in the primary
endpoint was demonstrated (HR 0.98, 95% CI 0.84, 1.14). At
trial end, for linagliptin as compared with glimepiride, there
was a 1.5 kg weight loss benefit, no difference in HbA1c or
introduction of glucose-lowering medications post-baseline,
and substantial benefits in terms of reductions in
hypoglycaemia, though serious hypoglycaemic events were
rare with glimepiride (0.45/100 patient-years) [15]. Paired
wi th o the r DPP-4 inh ib i t o r CVOTs , inc lud ing
Cardiovascular and Renal Microvascular Outcome Study with
Linagliptin (CARMELINA) [16], which demonstrated the
CV safety of linagliptin, this is a reassuring safety signal for
glimepiride, an inexpensive and effective sulfonylurea. It is
unclear whether these findings extend to other sulfonylureas.
Whereas we previously stated that there was limited
evidence for initial combination therapy, the Vildagliptin
Efficacy in Combination with Metformin for Early
Treatment of Type 2 Diabetes (VERIFY) trial provides addi-
tional information. The initial combination of the DPP-4
inhibitor vildagliptin and metformin was shown to provide
for a lower rate of secondary failure of glycaemic control to
HbA1c ≥53 mmol/mol (≥7%) vs metformin alone or the
sequential addition of metformin and vildagliptin [17]. We
now suggest that providers should engage in shared deci-
sion making around initial combination therapy in new-
onset cases of type 2 diabetes.
There are several major questions regarding the optimal
application of new diabetes drugs. One obvious question aris-
ing from recent trial results is whether combined use of GLP-1
receptor agonists and SGLT2 inhibitors provides additional
benefit for the prevention of MACE, CV death, hHF and
CKD progression. Three trials have demonstrated the
HbA1c-lowering and weight-reduction efficacy of the combi-
nation [18–20], but none addresses the impact of the combi-
nation of the two on cardiorenal endpoints. A second question
that arises from the recent secondary analyses of SGLT2
inhibitor studies is whether there are subsets of patients who
benefit disproportionately, or very little, from treatment with
the newer diabetes drugs. The emerging evidence that SGLT2
inhibitors may be particularly useful in preventing adverse
outcomes in patients with diabetes with HFrEF raises the
possibility of more targeted use of these agents. Finally, the
mechanism(s) of action bywhich GLP-1 receptor agonists and
SGLT2 inhibitors confer cardiorenal benefit in diabetes are not
understood. Research in this area will be very useful in
optimising the now clear potential of drugs for diabetes to
mitigate the cardiovascular and renal complications of the
disease. Modifications to the main figures of the prior publi-
cation are suggested as shown in Figs 1 and 2.
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